Online patient communities have become a vital resource for rare disease patients, and pharma is coming round to the idea of engaging with them for real-world data.
As coronavirus vaccines and treatments advance rapidly through research and development, the world starts to consider what drugs and digital tools might be needed in the ‘new normal’.
